Pharmaceuticals
Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee
LOS ANGELES, June 24, 2020 /PRNewswire/ -- Akeso, Inc. ("Akeso", 9926.HK) announced the appointment of ProfessorBradley J. Monk, MD, FACOG[1], FACS[2] as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee for its global Phase 2, multicentre registration study to evaluate the ef...
2020-06-24 12:55
7228
InxMed Released Research Data of "FAK inhibitor IN10018 overcomes drug resistance of KRAS G12C inhibition" at 2020 AACR Annual Meeting
SHANGHAI, June 24, 2020 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced that the company has released the research data of "FAK inhibitor IN10018...
2020-06-24 08:41
2113
IgNova Files Patent Application on Antibody Against COVID-19
VISBEK, Germany, June 24, 2020 /PRNewswire/ -- IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (I...
2020-06-24 02:13
1649
ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA
SAN DIEGO, June 22, 2020 /PRNewswire/ -- ABM Therapeutics, a clinical-stage biopharmaceutical company developing a new generation of BRAF inhibitor, today announced that the first cancer patient has been successfully enrolled and dosed with ABM-1310 in the Phase 1 clinical trial in theUSA. ABM-13...
2020-06-22 23:00
4243
Cutting-edge Multidisciplinary Approaches to Minimally Invasive Cancer Treatment Utilizing JCI MN COLLOIDAL IODINE (R) and Possible Effect on SARS-CoV-2
TOKYO, June 22, 2020 /PRNewswire/ -- On June 10, 2020, JCI MN IODINE Co., Ltd. released the following new information regarding the therapeutic usefulness of JCI MN IODINE agents.Ryusuke Fujiki, Clinical Head and President of Fujiki Hospital, announced "minimally invasive, multidisciplinary treat...
2020-06-22 13:00
1058
Qiming's Portfolio Company SinocellTech Lands on STAR Market
SHANGHAI, June 22, 2020 /PRNewswire/ -- Chinese biologic drug developer SinocellTech, Qiming's portfolio company, today lands on the Science and Technology Innovation Board (the STAR Market). The issue price of SinocellTech (SHSE: 688520) isCNY 25.64 per share. The stock opens at CNY 85 per share...
2020-06-22 12:20
2446
Innovent Announces The Stock Exchange of Hong Kong Limited Approved the "B" Marker Removal from the Company's Stock Symbol in the HKEX
SUZHOU, China, June 22, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announc...
2020-06-22 07:40
6159
Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors
SUZHOU, China and ROCKVILLE, Md., June 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and senescence diseases, today announced a clinical collaboration with Acerta P...
2020-06-22 07:15
2931
Ascentage Pharma Submits Its First New Drug Application to National Medical Products Administration, for HQP1351, the First Third-Generation BCR-ABL Inhibitor in China
SUZHOU, China and ROCKVILLE, Md., June 18, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that Guangzhou Healthquest P...
2020-06-18 17:30
2214
Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China
SUZHOU, China, June 18, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today annou...
2020-06-18 12:00
5140
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
HANGZHOU, China and SHAOXING, China, June 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that its partner Sagimet Biosciences Inc (Sagimet, formerly 3-V Biosciences Inc), announced today positive results on oral, once-daily non-alcoholic steatohepatitis (NASH) dru...
2020-06-17 20:30
3269
Ascentage Pharma Announces First Patient Dosed in the Phase II Clinical Study of IAP Antagonist APG-1387 in Combination with Entecavir for the Treatment of Patients with Chronic Hepatitis B
SUZHOU, China, and ROCKVILLE, MD., June 17, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase II clinical ...
2020-06-17 13:20
2478
ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Nicotinamide Riboside (NR)
LOS ANGELES, June 16, 2020 /PRNewswire/ -- ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and innovators behind Niagen® (patented nicotinamide riboside) science, announced today the publication of results from preclinical research on cells ...
2020-06-16 14:09
7111
New Capture the Fracture® Partnership Aims for 25% Reduction in the Incidence of Hip and Vertebral Fractures Due to Osteoporosis by 2025
International Osteoporosis Foundation Announces First-of-its-kind Partnership WithUniversity of Oxford, Amgen and UCB to Combat Global Public Health Burden of Osteoporosis[1] Hip and Vertebral Fractures are Costly for Society and Can be Life-Altering for Patients[2],[3] NYON, Switzerland...
2020-06-16 08:00
3127
Investigational, Once-weekly Insulin Icodec Showed Comparable Efficacy and Safety to Once-daily Insulin Glargine U100 in Phase 2 Trial
This material is intended for global medical media only, excl US For journalistic assessment and preparation before publication. BAGSVÆRD, Denmark, June 15, 2020 /PRNewswire/ -- Today, Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-week...
2020-06-15 07:30
1467
Switching to Ozempic(R) from another GLP-1 RA significantly reduced blood sugar and weight in people with type 2 diabetes in routine clinical practice
This material is intended for global medical media only, excl US. For journalistic assessment and preparation before publication. - A separate real-world study showed that people with type 2 diabetes on two oral antidiabetic drugs who intensified with a glucagon-like peptide-1 receptor agonist ...
2020-06-15 06:15
1539
Harbour BioMed Appoints Dr. Jon Wigginton to its Scientific Advisory Board
2020-06-11 18:00
4509
Menarini Group Completes a Solid Year of Operating Performance
- Turnover reaches €3,793 million, with an increase of 3.2% compared to 2018 and EBITDA of €492 million thanks to continued strong performance of its most important products - €150 million investment into new plant in Italy significantly increasing oral blister capacity in line with increased de...
2020-06-10 23:42
3086
Siemens and Exyte join forces to deliver integrated solutions for fast-track construction of smart biotech facilities
Joint Press Release * Covid-19 poses major challenges for developing and mass-producing vaccines and medicines in existing production facilities * Siemens and Exyte combine their strengths to offer intelligent, modular, and scalable biotech facilities * Siemens provides solutions for proces...
2020-06-10 08:45
4104
L.E.A.F. Pharmaceuticals Lead Investigational Product for Lung and Colorectal Cancers, LEAF-1401, Featured at the 2020 Virtual Annual Meeting of the American Society of Clinical Oncology (ASCO)
Treatment with LEAF-1401 exposes the tumor to 20-times more pentaglutamated pemetrexed than conventional pemetrexed. Polyglutamated pemetrexed has been shown to be 80-times more potent than pemetrexed in inhibiting thymidylate synthase (TS), a key enzyme in the folate pathway. Pemetrexed (Alimta®...
2020-06-10 03:15
1648
Week's Top Stories
Most Reposted
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 293 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 291 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
[Picked up by 279 media titles]
2024-11-08 20:11
Most Read
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
2024-11-12 09:00
5652
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
2024-11-11 21:00
5652
Sobot Introduces its All-in-One Solution at GITEX Global 2024
2024-11-12 11:00
5608